36 results about "Arterial Embolization" patented technology

The invention provides a medical device having a catheter and one or more expandable constricting/occluding members. The catheter is adapted for use with therapeutic or diagnostic devices, including an angioplasty/stent catheter and an atherectomy catheter. The constrictor/occluder is mounted at the distal end of the catheter. Manometers may be mounted distal to one or more constrictors for measuring pressure distal to the constrictor(s). Methods of using the devices for preventing distal embolization during extracranial or intracranial carotid procedures or vertebral artery procedures by reversing blood flow in an internal carotid artery, an external carotid artery, and/or a common carotid artery toward the subclavian artery are disclosed.

A catheter device fur diagnostic vascular treatment and/or therapeutic vascular treatment of a subject's vasculature having a blunt, atraumatic (non-traumatic) distal tip and orifice edge to the catheter. This will eliminate or mitigate catastrophic complications caused by contemporary catheters such as vascular dissection, thrombosis, distal embolization and vessel occlusion. The catheter tip can be shaped in various ways with solid material (compressible or non-compressible) or balloon inflation devices to create a blunt, atraumatic (non-traumatic) tip and orifice, and may include a set-back region as well.

The invention provides a core-shell type pre-charged chemotherapy medicine embolization microsphere and a preparation method thereof. The method comprises the following steps of using water/oil/water(W/O/W) complex emulsion type or oil/water/oil (O/W/O) complex emulsion type emulsified micro liquid drips as templates; coating tiny liquid drips containing medicine into outer layer liquid drips; high molecular polymers in the inner and outer layer liquid drips are converted through measures such as physical measures and chemical measures to form an inner layer core and an outer layer shell. Theformed core-shell structure medicine microsphere is formed by polymers of two-layer structures; the inner core contains medicine; the outer shell is favorable for maintaining the activity of the inner core medicine; the stable medicine release is realized; the sudden release is prevented; the safety is enhanced. The medicine carried microsphere prepared by the method has the advantages that the particle diameter range is 10 to 1000 micrometers; the sphere degree is good; the particle diameter is uniform; (the dimension deviation is 5 percent); the medicine encapsulation rate is high; the structure/carried medicine is controllable; meanwhile, the preparation method of the pre-charged chemotherapy medicine embolization microsphere can provide a novel idea for the clinic application study ofthe transcatheter arterial embolization.

The invention relates to the technical field of medical plastic surgery, in particular to the technical field of facial filling and anti-wrinkle, in particular, it is an injection filling cosmetic modification anti-aging, skin beautification and facial rejuvenation material. The preparation formula of the present invention includes hyaluronic acid, collagen, vitamin E and PLGA. The preparation method comprises: 1) preparing high-viscosity gel; 2) preparing PLGA nano-microspheres; 3) fully mixing high-viscosity gel and PLGA nano-microspheres; 4) sterilizing and filling. Compared with the prior art, the present invention has the beneficial effect that: the combined use of collagen and hyaluronic acid reduces skin erythema, swelling, hardening or itching, muscle pain, urticaria or Other symptoms such as rash. It reduces the probability of severe complications such as peripheral blood circulation embolism, skin necrosis, retinal artery embolism, and cardiocerebral artery embolism that may be caused by simple hyaluronic acid injection, and the safety of product use is improved.

The invention relates to an improved method for preparing an artery embolic agent, which comprises the following steps: mixing 8ml of a doxorubicin hydrochloride solution containing 15-20 percent (by volume) of Span-80 used as a surface active agent and having concentration of 5-10g/L with 16ml of iodized oil used as an oily contrast agent at 23-25 DEG C; adding calcium carbonate to 10ml of a sodium alginate solution with concentration of 1-2 percent expressed in percentage by weight so as to enable the calcium carbonate to have the concentration of 2-3 percent expressed in percentage by weight; mixing the solutions prepared in the two steps according a volume ratio of 1:1.3; and mixing an obtained solution with liquid paraffin according to a volume ratio of 1:1.9-1:5 to obtain a product. Shown by testing, compared with a contrast group, the embolic agent obviously slows down tumor growth, and the tissue of a visible tumor has liquefactive necrosis, thus the embolic agent can obviously prolong the life time of a liver cancer animal model.

The invention relates to the technical field of medicaments, and discloses a transcatheter arterial chemoembolization embolism agent containing an autophagy inhibitor for treating liver cancer. The embolism agent consists of a chemotherapy medicament, the autophagy inhibitor and iodized oil, wherein the chemotherapy medicament is cis-platinum; the iodized oil is liquid iodized oil; and the autophagy inhibitor is selected from bafilomycin A1 or chloroquine. The bafilomycin A1 or the chloroquine can be used as a sensitizer of the chemotherapy medicament, and can increase the sensitivity of liver cancer cells to the chemotherapy medicament in a hypoxic ischemic microenvironment after embolism and enhance the anti-cancer effect of the chemotherapy medicament. Animal experiments show that the embolism agent can achieve good curative effect for treating middle and late primary liver cancers, obviously increase the apoptosis rate and the necrosis rate of tumor cells and remarkably reduce tumors so as to improve the curative effect of transcatheter arterial chemoembolization. The invention provides the embolism agent with good curative effect and low injury for the transcatheter arterial chemoembolization.

The invention relates to the technical field of drugs and aims to provide a new use of nafamostat mesilate in preparing drugs for preventing and curing ischemic cerebral apoplexy. Preoperative preventative administration or postoperative therapeutic administration is performed on a classical permanent cerebral ischemia model (permanent middle cerebral artery occlusion-pMCAO) and a classical cerebral ischemia reperfusion model (transient middle cerebral artery occlusion-tMCAO) by the invention, respectively, and the results show that the nafamostat mesilate is remarkable in effect of resisting the ischemic cerebral apoplexy. At a dosage point appointed by experiments, the nafamostat mesilate can be used for obviously improving animal behavior dysfunctions caused by ischemia and lowering the cerebral infarction rate of permanent cerebral ischemia and cerebral ischemia reperfusion rats. Prompted by research results, the nafamostat mesilate can be used for preventing and curing the ischemic cerebral apoplexy.

The invention discloses an aneurism embolization device and an aneurism embolization system. The aneurism embolization device comprises a braided part arranged in the neck of an aneurism and fitting the same, and a support arranged in a parent artery at the neck of the aneurism; one end of the support is connected with the braided part; the other end of the support is connected with a push guide wire during interventional operation; the braided part and the support are delivered to the vascular lesion part through a micro catheter during interventional operation. Compared with the prior art, the aneurism embolization device has the advantages of lowered occupation effect, lower cost, adaptability to aneurisms different in shape at different parts, and lower risk of blocking of other branches and delayed cracking of the arteries.

The invention discloses a pair of uterus haemostatic forceps. The uterus haemostatic forceps include two rectangular forceps heads, two curve forceps rods, a rotation shaft, two forceps arms and two handles; the rectangular forceps heads are of hollow rectangular structures and are arranged at the front end of the curve forceps rods; the curve forceps rods are convex curve-shaped, and the tails of the curve forceps rods are connected to the forceps arms; the tail ends of the forceps arms are provided with the handles; the rotation shaft is arranged between the curve forceps rods and the forceps arms, can allow the two curve forceps rods and the forceps arms to be connected in a cross manner and open and close along the rotation shaft, wherein after closure, the two rectangular forceps heads are attached to each other tightly, and a hollow structure is form between the two curve forceps rods. The uterus haemostatic forceps are novel in structure, is easy to operate, can be used for clamping Caesarean delivery (after delivery of baby) corpus uteri, in particular to the front and back walls of the lower section of the uterus, can achieve a compression hemostasis effect on the whole organ so as to prevent short-term excessive bleeding of placenta attachment sites, can match uterine artery embolisation, hysterectomy and call aid treatment, and ensure life safety of puerperae.

The invention provides an application of a flavonoid glycoside compound on a medicine for treating cerebral apoplexy. A compound with a structure represented by a formula I is apigenin-7-O-beta-D-(6''-p-coumaroyl)-glucopy ranoside. The pharmacological test results prove that the compound has an obvious protection effect on ischemic injury caused by a middle cerebral artery occlusion (MACO) model and is free from toxic and side effects. The application of the flavonoid glycoside compound on the medicine for treating the cerebral apoplexy provided by the invention can provide a lead compound for preparing new medicines for protecting cerebral ischemic injury, so that the flavonoid glycoside compound can be a new medicine for treating the cerebral apoplexy.

The present invention provides an agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis of giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma, a local infusion for artery embolization, and an artificial bone, which comprises a substance having a PPARγ-agonistic activity and/or a PPARγ expression-inducing activity as an active ingredient. The agent for prophylactic treatment, therapeutic treatment, or prevention of metastasis, the local infusion for artery embolization, and the artificial bone of the present invention are a radical therapeutic agent or radical therapeutic material that can cause apoptosis in giant cell tumor occurring in a bone and soft tissue, chondrosarcoma, or bone sarcoma to make the tumor disappear, and can induce differentiation of the tumor into fat cells to make the tumor disappear.

Disclosed is an antitumor agent or postoperative adjuvant chemotherapeutic agent for a hepatocellular carcinoma patient who underwent transarterial embolization. Specifically disclosed is an antitumor agent or a postoperative adjuvant chemotherapeutic agent, which contains TSU-68 or a salt thereof and can be administered to a hepatocellular carcinoma patient, who has undergone transarterial embolization, within two weeks after the operation.

The invention relates to a tube and wire combined vena cava filter, which comprises a guide tube and at least three guide wires. The guide wires all arranged in the guide tube and penetrate the guide tube; first ends of the guide wires extend out from the front end of the guide tube and woven fixedly to form a network structure; second ends, opposite to the first ends, of the at least three guide wires are provided with recovery hooks; the recovery hooks extend out from the rear end of the guide tube, and the recovery hooks face outwards and are uniformly distributed on the periphery of the guide tube. The guide wires are woven into the network structure for filtering large thrombi, and auxiliary filter and protection of the guide wires are realized by virtue of the guide tube, so that the large thrombi can be filtered effectively to prevent pulmonary embolism while structural stability, high strength, low cost and simplicity in manufacturing are realized. In addition, due to the three recovery hook structures, one of the recovery hooks is always not close to the blood vessel wall no matter what position and posture of the vena cava filter are in the vena cava, and accordingly the recovery hooks can be conveniently caught by a catching ring, and convenience in recovery of the whole filter is achieved.

This invention provides a method for causing weight loss in a subject comprising introducing biodegradable microspheres into one or more of the subject's gastric arteries, wherein the microspheres (i) have a d₉₀ value from 40 μm to 500 μm; (ii) comprise polylactic acid (PLA) and/or polylactic co-glycolic acid (PLGA); (iii) carry a therapeutically effective amount of pharmaceutical octreotide; (iv) embolize gastric arterial vessels supplied by the one or more arteries into which they are introduced; and (v) release octreotide during embolization.

The invention discloses application of ramelteon in preparation of a drug for treating ischemic brain injury. Ramelteon can alleviate acute focal cerebral ischemic injury and neurological dysfunctioncaused by permanent middle cerebral artery embolization in mice, inhibit pathological inflammatory response, and promote neural functional recovery in the late stage of ischemia. The use of ramelteonis achieved primarily by the following mechanism: ramelteon can inhibit cell autophagy during cerebral ischemia and reduces autophagic death of neurons by stimulating the MT2 melatonin receptor; in addition, ramelteon can also inhibit the release of inflammatory factors secondary to cerebral ischemia, reduce inflammatory cell damage, and ultimately exert a therapeutic effect against cerebral ischemia. The application provided by the invention has the beneficial effects of providing a new use of ramelteon, and providing a basis for screening new drugs.

The present invention provides a method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients who have been treated with transarterial embolization and an antitumor agent for treating cancer patients who have been predicted to have a high probability of obtaining sufficient therapeutic effects from such chemotherapy. The present invention also provides a method for predicting therapeutic effects of chemotherapy on hepatocellular carcinoma patients who have been treated with transarterial embolization using the expression level of PDGF-BB or IL-8 as an indicator and an antitumor agent for treating cancer patients who have been predicted to have a high probability of obtaining therapeutic effects by such prediction method.

The invention relates to a slow-release topoismerase inhibitor gel injection which contains an anticancer-effective amount of topoismerase inhibitor microspheres (or microsphere and topoismerase inhibitor micropowder), an amphiphilic block polymer composed of polyethylene glycol and polyester, a solvent and a certain amount of slow-release regulator. The amphiphilic block polymer aqueous solution is liquid at the room temperature and turns into a semisolid or solid biodegradable water-insoluble gel in vivo in warm-blooded animals, so that the topoismerase inhibitor encapsulated therein is sustainedly and locally released around the tumor and the microspheres can further control the slow release for a plurality of weeks to a plurality of months. After the intratumoral injection or peritumoral injection or post-operative intracavitary injection or arterial embolization, the slow-release topoismerase inhibitor gel injection can significantly reduce the general drug reaction and selectively enhance the curative effect of non-operative treatment such as chemotherapy and radiotherapy, and is used for the treatment of tumors of different stages. The topoismerase inhibitor is selected from camptothecin, topoteean, etoposide, teniposide, esorubicin, pirarubicin and valrubicin.